All DOACs |
All DOACs |
All DOACs |
All DOACs |
All DOACs |
All DOACs |
All DOACs |
All DOACs |
Age ≥80 years |
0.43 |
0.83 |
0.56-1.21 |
Age ≥80 years |
0.16 |
0.60 |
0.36-1.02 |
Benzodiazepines |
0.34 |
1.22 |
0.84-1.78 |
Male sex |
0.90 |
1.19 |
0.72-1.97 |
Diabetes |
0.64 |
1.09 |
0.73-1.63 |
Surgery |
0.16 |
0.61 |
0.35-1.06 |
CHA2DS2-VASc |
0.08 |
1.17 |
1.05-1.30 |
CHA2DS2-VASc |
0.43 |
0.92 |
0.76-1.10 |
Heart failure
|
0.55
|
1.12
|
0.77-1.64
|
Weight
<60 kg
≥60 kg (REF)
|
<0.01
|
2.34
|
1.42-3.85
|
Weight
<60 kg
≥60 kg (REF)
|
0.02
|
0.46
|
0.27-0.77
|
DOAC
Dabigatran
Apixaban
Rivaroxaban (REF)
|
0.04
<0.01
|
0.24
0.18
|
0.08-0.71
0.10-0.32
|
DOAC
Edoxaban
Rivaroxaban (REF)
|
<0.01
|
0.42
|
0.24-0.74
|
Renal function (CrCl)
<50 mL/min
≥50 mL/min (REF)
|
<0.01
|
11.29
|
6.23-20.45
|
Surgery |
0.05 |
0.57 |
0.37-0.87 |
|
|
|
|
Narcotic analgesics |
0.04 |
1.67 |
1.13-2.46 |
|
|
|
|
Bleeding history |
0.02 |
1.86 |
1.24-2.80 |
|
|
|
|
Initiation at hospital |
<0.01 |
0.45 |
0.29-0.71 |
|
|
|
|
DABIGATRAN |
DABIGATRAN |
DABIGATRAN |
DABIGATRAN |
DABIGATRAN |
DABIGATRAN |
DABIGATRAN |
DABIGATRAN |
Diabetes
|
0.14
|
2.79
|
0.94-8.29
|
Weight
<60 kg
≥60 kg (REF)
|
0.27
|
4.14
|
0.48-35.49
|
Narcotic analgesics
|
0.06
|
3.52
|
1.23-10.12
|
Renal function (CrCl)
<50 mL/min
≥50 mL/min (REF)
|
0.16
|
8.08
|
0.73-88.84
|
RIVAROXABAN |
RIVAROXABAN |
RIVAROXABAN |
RIVAROXABAN |
RIVAROXABAN |
RIVAROXABAN |
RIVAROXABAN |
RIVAROXABAN |
Surgery |
0.30 |
0.63 |
0.30-1.32 |
Age ≥80 years |
0.16 |
0.43 |
0.16-1.14 |
Bleeding history
|
0.29
|
1.68
|
0.74-3.77
|
Weight
<60 kg
≥60 kg (REF)
|
0.48
|
1.47
|
0.60-3.62
|
Initiation at hospital |
0.08 |
0.21 |
0.05-0.91 |
CHA2DS2-VASc |
0.26 |
0.82 |
0.62-1.09 |
Age ≥80 years
|
0.06
|
2.34
|
1.15-4.74
|
Renal function (CrCl)
<50 mL/min
≥50 mL/min (REF)
|
<0.01
|
100.95
|
23.23-438.70
|
Renal function (CrCl)
<50 mL/min
≥50 mL/min (REF)
|
<0.01
|
0.17
|
0.06-0.48
|
|
|
|
|
APIXABAN |
APIXABAN |
APIXABAN |
APIXABAN |
APIXABAN |
APIXABAN |
APIXABAN |
APIXABAN |
Hypertension |
0.46 |
1.32 |
0.72-2.43 |
Age ≥80 years |
0.51 |
0.62 |
0.19-2.07 |
Diabetes
|
0.21
|
1.50
|
0.89-2.52
|
Weight
<60 kg
≥60 kg (REF)
|
0.56
|
1.34
|
0.57-3.19
|
Renal function (CrCl)
<50 mL/min
≥50 mL/min (REF)
|
0.08
|
1.80
|
1.06-3.04
|
Renal function (CrCl)
<50 mL/min
≥50 mL/min (REF)
|
0.08
|
4.37
|
1.13-16.91
|
Heart failure |
0.08 |
1.78 |
1.07-2.96 |
Surgery |
0.26 |
0.25 |
0.03-1.92 |
Weight
<60 kg
≥ 60 kg (REF)
|
<0.01
|
0.26
|
0.12-0.55
|
Heart failure
|
0.64
|
1.27
|
0.52-3.10
|
Bleeding history |
0.03 |
2.14 |
1.22-3.75 |
CHA2DS2-VASc |
0.90 |
0.98 |
0.68-1.41 |
|
|
|
|
HAS-BLED |
0.26 |
1.42 |
0.85-2.35 |
EDOXABAN |
EDOXABAN |
EDOXABAN |
EDOXABAN |
EDOXABAN |
EDOXABAN |
EDOXABAN |
EDOXABAN |
Surgery |
0.20 |
0.36 |
0.10-1.33 |
Surgery |
0.13 |
0.48 |
0.20-1.18 |
Initiation at hospital |
0.12 |
0.36 |
0.12-1.03 |
CHA2DS2-VASc |
0.23 |
0.79 |
0.58-1.08 |
HAS-BLED |
0.90 |
0.96 |
0.52-1.77 |
HAS-BLED |
0.56 |
1.02 |
0.64-1.63 |
CHA2DS2-VASc |
0.08 |
1.48 |
1.02-2.14 |
Male sex |
0.16 |
0.52 |
0.24-1.12 |
Narcotic analgesics
|
0.08
|
2.98
|
1.14-7.80
|
Weight
<60 kg
≥ 60 kg (REF)
|
<0.01
|
4.16
|
1.97-8.77
|
|
|
|
|
Renal function (CrCl)
<50 mL/min
≥50 mL/min (REF)
|
0.01
|
3.25
|
1.49-7.12
|